Filing Details

Accession Number:
0000950170-24-084003
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-16 18:00:31
Reporting Period:
2024-07-15
Accepted Time:
2024-07-16 18:00:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR Biological Products, (No Disgnostic Substances) (2836) 812992166
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821198 Jared Gollob C/O Kymera Therapeutics, Inc.
500 North Beacon Street, 4Th Floor
Watertown MA 02472
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-07-15 16,455 $2.08 112,195 No 4 M Direct
Common Stock Disposition 2024-07-15 16,455 $45.15 95,740 No 4 S Direct
Common Stock Acquisiton 2024-07-16 23,145 $2.08 118,885 No 4 M Direct
Common Stock Disposition 2024-07-16 13,281 $45.59 105,604 No 4 S Direct
Common Stock Disposition 2024-07-16 9,864 $46.10 95,470 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-07-15 16,455 $0.00 16,455 $2.08
Common Stock Stock Option (Right to Buy) Disposition 2024-07-16 23,145 $0.00 23,145 $2.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
46,028 2029-05-22 No 4 M Direct
22,883 2029-05-22 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.02 to $46.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.02 to $46.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.